6:18 PM
Mar 23, 2007
 |  BC Extra  |  Clinical News

Hana off on pipeline update

HNAB fell $1.31 (35%) to $2.41 on a newsy Friday that saw the company pull an NDA for one compound, suspend development of another and update its development plans for a third. HNAB is withdrawing an NDA for Zensana ondansetron to prevent chemotherapy, radiation and post-operative induced nausea and vomiting, following a review of a previously reported precipitation issue ...

Read the full 286 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >